Jalra-M 50mg/500mg Tablet is a combination oral antihyperglycemic agent containing Metformin 500mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control compared to monotherapy. Jalra-M is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled on either agent alone. It is important to monitor renal function prior to initiation and periodically during therapy due to the risk of lactic acidosis associated with Metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Vildagliptin is generally well tolerated but may occasionally cause headache or nasopharyngitis. Jalra-M should be used cautiously in patients with hepatic impairment and contraindicated in those with severe renal dysfunction. Proper adherence to prescribed dosage and lifestyle modifications are essential for optimal therapeutic outcomes.